Hedgepath Pharmaceuticals Inc (HPPI) financial statements (2021 and earlier)

Company profile

Business Address 4830 W. KENNEDY BLVD.
TAMPA, FL 33609
State of Incorp. DE
Fiscal Year End December 31
SIC 8731 - Commercial Physical and Biological Research (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1107100
Cash and cash equivalents1107100
Prepaid expense0000000
Deposits current assets  00   
Total current assets:1117100
Noncurrent Assets
Other noncurrent assets00000  
Total noncurrent assets:00000  
TOTAL ASSETS:1117100
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities0010000
Accounts payable0010000
Accrued liabilities     0 
Interest and dividends payable00     
Due to related parties      0
Other liabilities0000000
Other undisclosed current liabilities     (0)0
Total current liabilities:0110001
Noncurrent Liabilities
Liabilities, other than long-term debt3      
Deferred revenue3
Other undisclosed noncurrent liabilities 1     
Total noncurrent liabilities:31     
Total liabilities:3110001
Stockholders' equity
Stockholders' equity attributable to parent, including:(3)00700(1)
Common stock0000000
Additional paid in capital49494850373227
Accumulated deficit(56)(53)(48)(43)(36)(32)(28)
Other undisclosed stockholders' equity attributable to parent44    0
Total stockholders' equity:(3)00700(1)
TOTAL LIABILITIES AND EQUITY:1117100

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Operating expenses(3)(5)(5)(7)(4)(4)(2)
Operating loss:(3)(5)(5)(7)(4)(4)(2)
Interest and debt expense     (0)(0)
Loss before gain (loss) on sale of properties:(3)(5)(5)(7)(4)(4)(2)
Other undisclosed net income00     
Net loss:(3)(5)(5)(7)(4)(4)(2)
Other undisclosed net income attributable to parent  00  0
Net loss available to common stockholders, diluted:(3)(5)(5)(7)(4)(4)(2)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(3)(5)(5)(7)(4)(4)(2)
Comprehensive loss, net of tax, attributable to parent:(3)(5)(5)(7)(4)(4)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: